“Lilly Canada stands behind Ebglyss as a first-line biological therapy for the treatment of atopic dermatitis and we remain committed ... Try Now>> See today’s best-performing stocks on TipRanks >> ...

It has a 5% nourishing serum in it along with colloidal oatmeal and was co-created by dermatologists who get it. The best ...

"This strategic transaction brings together Biosion's and Aclaris' innovative programs with Aclaris' development capabilities ...

ZORYVE cream 0.15% is the first once-daily, Food and Drug Administration (FDA)-approved topical treatment for mild to moderate atopic dermatitisZORYVE, a next-generation topical phosphodiesterase-4 ...

The following is a summary of “Comparative safety of oral Janus kinase inhibitors versus dupilumab in patients with atopic ...

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, today announced that the first subject has been dosed in ...

Eli Lilly’s Ebglyss (lebrikizumab-lbkz) showed improvement in skin clearance and itch relief for most patients with ...

Organon reported solid Q3 2024 results with 4% revenue growth, driven by strong volume growth. Check out why I upgraded OGN ...

Whatever TikTok trends or buzzy skin-care ingredients are out there, heed this piece of advice: Don't compromise your barrier ...

BioSpace takes a look at the headlines across a heavy earnings week for biotechs, checking in on Allogene, Rapport and more.

Continued execution across all programs, including positive results up to nine months from APG777 Phase 1 trial that continue to support potential best-in-class profile On track to report Phase 2 Part ...

Apogee Therapeutics' APG777 shows promise in treating atopic dermatitis with less frequent dosing. See why I rate APGE stock ...